SCHEMBL15980353

SCHEMBL15980353

Cc1cc2c(o1)CCC(C)C2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
CYP2A6 P11509 2/20 0.41
CYP2A13 Q16696 1/20 0.41
TSHR P16473 1/20 0.41
NPC1 O15118 4/20 0.35
RAB9A P51151 4/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
KDM4E B2RXH2 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
PKM P14618 1/20 0.35
GFER P55789 1/20 0.35
TP53 P04637 1/20 0.32
MAPT P10636 1/20 0.32
THRB P10828 1/20 0.32
GAA P10253 2/20 0.31
LMNA P02545 1/20 0.31
GLA P06280 1/20 0.31
HPGD P15428 1/20 0.31
CASP1 P29466 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15980347 0.85 ALDH1A1 (0.44) ALDH1A1CYP2A6CYP2A13TSHRNPC1
SCHEMBL10160746 0.69 TSHR (0.33) ALDH1A1TSHRNPC1RAB9ASMN1; SMN2
SCHEMBL13677132 0.67 ALDH1A1 (0.42) ALDH1A1CYP2A6CYP2A13TSHRNPC1
SCHEMBL20690606 0.65 MEN1 (0.39) ALDH1A1CYP2A6CYP2A13TSHRNPC1
SCHEMBL14908333 0.65 CYP2A6 (0.37) ALDH1A1CYP2A6CYP2A13TSHRNPC1
SCHEMBL79036 0.63 ALDH1A1 (0.42) ALDH1A1CYP2A6CYP2A13NPC1RAB9A
SCHEMBL597666 0.63 SRD5A1 (0.42) ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL22043272 0.63 ALDH1A1 (0.38) ALDH1A1CYP2A6CYP2A13TSHRNPC1
SCHEMBL28736052 0.63 ALDH1A1 (0.76) ALDH1A1CYP2A6CYP2A13TSHRSMN1; SMN2
SCHEMBL28304501 0.63 DRD2 (0.37) ALDH1A1CYP2A6CYP2A13TSHRNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9133129-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-09-15 US disclosed
US-9133129-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-09-15 US disclosed
US-20140243310-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-08-28 US disclosed
US-20140243310-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243310-A1 BICYCLIC COMPOUND BICRA, NR3C2, CYP11B2 ALDH1A1 450/4885CYP2A6 426/4885CYP2A13 289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.